Recursion (RXRX) Q3 2026 Earnings Call Transcript

Recursion (RXRX) reported Q3 2026 earnings, highlighting clinical data for REC-4881 and REC-1245. REC-4881 showed significant reductions in polyp burden and safety. REC-1245 demonstrated early activity in solid tumors. The company secured $535M in partner cash inflows and extended cash runway to 2029. Operating expenses for 2026 were lowered to $375M, with 2027 expected under $360M. Sanofi and Roche collaborations advanced, with milestones and royalties. Fred Hassan was appointed board chair.

Original reporting
Published Nov 3, 2026, 8:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 9:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Recursion (RXRX) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$RXRXBullishMed
01

Why it matters

The disclosed data and financing could drive short-term price movement and influence biotech sector sentiment.

02

Market read

Recursion's new data and capital raise provide fresh material for traders, with potential upside in the biotech space.

03

What to watch

Potential regulatory hurdles for the new oral small molecule and execution risk on upcoming Phase I trials.

Relevance 8/10Novelty 8/10Timing: post-earnings today

Background

Recursion presented early clinical results, partnership milestones, and financial updates during its Q3 2026 earnings call.

Company-level read

Ticker impact

$RXRXBullishHigh confidence
Context

Recursion's Q3 2026 earnings call disclosed updated clinical data for programs REC-4881 and REC-1245, a $200M financing, lowered 2026 expense guidance, and a new board chair appointment.

Expected impact

likely upward pressure as investors price in new data and financing

Evidence & confidence

New trial data and a sizable financing round are fresh material that can move the stock, and expense guidance reduction improves outlook.

Market effects

Highlights AI-driven drug discovery progress, potentially boosting biotech sector sentiment.

US biotech investors may react; limited immediate impact on broader markets.

Shows growing partnership activity with global pharma firms (Sanofi, Roche).

Counterpoint

If the clinical data fails to translate into later-stage success, the financing may dilute existing shareholders.

Key entities

  • Recursion Pharmaceuticals

    Biotech firm focused on AI-driven drug discovery.

Related articles

$RXRXMed

Recursion Aligns With FDA On Phase 3 Trial Design For FAP Drug REC-4881; Stock Up

Recursion Pharmaceuticals (RXRX) aligned with the FDA on the Phase 3 trial design for REC-4881, an oral MEK1/2 inhibitor for familial adenomatous polyposis (FAP). The trial, expected to start in late 2027, will assess composite event-free survival as the primary endpoint. REC-4881 has shown a 47% median reduction in total polyp burden in Phase 1b/2 trials. RXRX shares were up 4.41% in premarket trading.

$RXRXMedAI 8/10

What Recursion Pharmaceuticals (RXRX) Said on Its Q3 Earnings Call

Recursion Pharmaceuticals (RXRX) reported Q3 updates, including 55% and 50% median reductions in upper and lower GI polyp burdens, respectively. REC-1245 showed partial responses in advanced solid tumors. Sanofi exercised an option, triggering a $10M payment. RXRX raised $200M in financing, extending cash runway into 2029. The company expects to start a registrational study in 2H 2027.

$RXRXHighAI 8/10

Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues

Recursion Pharmaceuticals reported a narrower-than-expected Q3 2026 loss of 22 cents per share, with revenues of $18.55 million, up 258.5% YoY, driven by a $10 million Sanofi milestone payment. Operating expenses declined, and the company advanced its pipeline, including REC-4881 and REC-1245. RXRX shares are down 6.4% YTD.

$RXRXMedAI 8/10

Recursion Pharma Q3 Net Loss Narrows, Reports Positive REC-4881 Data; Advances Pipeline

Recursion Pharmaceuticals (RXRX) reported Q3 2026 net loss narrowed to $119.0M from $162.3M YoY. Revenue rose to $18.55M, driven by a $10M Sanofi milestone payment. REC-4881 showed positive FAP trial results, with significant polyp burden reductions. REC-1245 demonstrated preliminary efficacy in cancers. RXRX expects cash to last into 2029. Stock is down 4.96% to $3.83.